Kopran Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹211 Cr +79.2% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
K

Kopran Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Kopran Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹118Cr
−22.2% YoY
−12.8% QoQ
Net profit
−₹10Cr
Q2 FY25: ₹7 Cr
Margin
−4.48%
−14.2 pp YoY
−14.9 pp QoQ

Kopran Ltd Q2 FY26 key numbers

Revenue
Revenue from Operations for Q2 FY 2025-26: Rs. 11,791 lakhs.

As stated in Kopran Ltd's Q2 FY26 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Kopran Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹271
Market cap₹1.3K Cr
P/E53.7

The short version

Revenue from Operations for Q2 FY 2025-26: Rs. 11,791 lakhs. Quarter (Q2 FY 2025-26) Financials (Page 5):.

From Kopran Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Revenue from Operations for Q2 FY 2025-26: Rs. 11,791 lakhs
  • Revenue from Operations for Q2 FY 2024-25: Rs. 15,156 lakhs
  • Year-on-year change: Decline of Rs. 3,365 lakhs (~22.2% decrease)
  • Sales/Other Income (HY figures):
  • HY FY 2025-26: Rs. 25,331 lakhs
  • HY FY 2024-25: Rs. 63,359 lakhs
  • Formulations Segment Revenue (Q2 FY 2025-26): Rs. 4,017 lakhs
  • Formulations Segment Revenue (HY FY 2025-26): Rs. 9,095 lakhs

2 more points from Kopran Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Kopran Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Kopran Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Kopran Ltd said on order book & pipeline — free account, 30 seconds.

Kopran Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Kopran Ltd Q2 FY26 results — key figures

Kopran Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue118152-22.2%135-12.8%
Operating profit (EBITDA)-515-135.8%14-137.4%
Operating margin-4.48%9.72%-14.2 pp10.45%-14.9 pp
Profit before tax-1210-220.4%10-217.5%
Net profit (PAT)-107-234.4%7-233.2%
EPS (₹)-2.061.53-234.6%1.54-233.8%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹211 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Kopran Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Kopran Ltd Q2 FY26 results?

Revenue from Operations for Q2 FY 2025-26: Rs. 11,791 lakhs. Quarter (Q2 FY 2025-26) Financials (Page 5):.

What is Kopran Ltd share price analysis?

Kopran Ltd currently shows a neutral. The stock trades at a P/E of 53.7 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.